Article

Immune Modulation Facilitates Repair, Regeneration of Retinal Cells

Author(s):

“MANF supplementation to photoreceptors transplanted into congenitally blind mice increased integration efficiency and accelerated and improved visual function recovery,” according to the study.

Macular degeneration, blindness, ophthalmology, stem cells, ophthalmologists, retinal degeneration, immune modulation

First noticing it in flies, researchers from the Buck Institute claim to have found a previously undetected immunomodulatory function that could be useful in undoing the damage wrought on our eyes over time. Mesencephalic astrocyte-derived neurotrophic factor (MANF) contains the function, which is able to convert inflammatory immune cells into reparative cells.

Researchers determined MANF was secreted in flies as an immune response to retinal damage, and was observed to begin the transition from inflammation to repair. The same process was seen to occur in mammals, and studies are ongoing in mouse and human cells.

The hope of this study is that MANF can both promote healing and facilitate more successful cell transplantation, which could benefit a wide array of age-related health conditions.

Currently, the success of stem cell implantation has been extremely limited (in the testing that has been done on mice), because only approximately 1% of transplanted cells survive their new environments. MANF may significantly change that success rate. Results so far are promising: “MANF supplementation to photoreceptors transplanted into congenitally blind mice increased integration efficiency and accelerated and improved visual function recovery,” according to the study.

“Focusing on immune modulation to promote a healthy repair response to tissue damage rather than a deleterious inflammatory response is a new frontier in aging research,” says Heinrich Jasper, PhD, Chief Scientific Officer at the Institute. The study highlights how valuable integrated research on both invertebrates and vertebrates alike can be in opening the doors to significant advancements.

Related Videos
A panel of 3 experts on dry eye
A panel of 3 experts on RVO
HCPLive Five at ASRS 2024 | Image Credit: HCPLive
Jordana Fein, MD: Pre-Dose IOP Outcomes After Aflibercept 8 mg for DME | Image Credit: LinkedIn
Diana Do, MD: Impact of Baseline BCVA on Aflibercept 8 mg Outcomes in DME | Image Credit: Stanford University
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.